https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49965 Wed 21 Jun 2023 11:57:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19108 Wed 11 Apr 2018 16:00:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22877 Wed 11 Apr 2018 13:19:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26547 in vitro and in vivo. PI staining showed significant apoptosis in NPC cells accompanied by the overproduction of ROS and downregulation of mitochondrial membrane potential (MMP, ΔΨm) by 3-BrPA. However, the ROS scavenger N-acetyl-L-cysteine (NAC) significantly reduced 3-BrPA-induced apoptosis by decreasing ROS and facilitating the recovery of MMP. We elucidated the molecular mechanisms underlying 3-BrPA activity and found that it caused mitochondrial dysfunction and ROS production, leading to necroptosis of NPC cells. We investigated the effects of the caspase inhibitor z-VAD-fmk, which inhibits apoptosis but promotes death domain receptor (DR)-induced NPC cell necrosis. Necrostatin-1 (Nec-1) inhibits necroptosis, apparently via a DR signaling pathway and thus abrogates the effects of z-VAD‑fmk. In addition, we demonstrated the effective attenuation of 3-BrPA-induced necrotic cell death by Nec-1. Finally, animal studies proved that 3-BrPA exhibited significant antitumor activity in nude mice. The present study is the first demonstration of 3-BrPA-induced non-apoptotic necroptosis and ROS generation in NPC cells and provides potential strategies for developing agents against apoptosis‑resistant cancers.]]> Wed 11 Apr 2018 11:05:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30132 Wed 09 Feb 2022 15:54:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36167 Mon 26 Oct 2020 11:55:19 AEDT ]]>